Lesion Specific Radiomics Analysis Shows Promising Results For Early Stage Efficacy Assessment On Metastatic Lesions

Radiomics is an image-based approach that allows for characterization and quantification of tumor lesions in cancer patients. Radiomics has been proven capable of potentially adding value in the diagnostic and prognostic patient management [1]. In this study we evaluated the potential of Radiomics to bring additional insight also in early drug development by investigating the evolution of all the lesions of the lungs and the liver of the patients from baseline (T0) to post-treatment (T1) CT-Scan. This is particularly important in cancer with high burden of disease and where standard RECIST evaluation fails to detect mono therapeutic activity of a novel anti-cancer agent.